393 related articles for article (PubMed ID: 36913180)
1. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
Núñez P; Quera R; Yarur AJ
Drugs; 2023 Mar; 83(4):299-314. PubMed ID: 36913180
[TBL] [Abstract][Full Text] [Related]
2. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.
Nakase H
Immunol Med; 2023 Sep; 46(3):121-130. PubMed ID: 37036140
[TBL] [Abstract][Full Text] [Related]
3. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
4. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.
Cordes F; Foell D; Ding JN; Varga G; Bettenworth D
World J Gastroenterol; 2020 Jul; 26(28):4055-4075. PubMed ID: 32821070
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
D'Amico F; Fiorino G; Furfaro F; Allocca M; Danese S
Expert Opin Investig Drugs; 2018 Jul; 27(7):595-599. PubMed ID: 29938545
[TBL] [Abstract][Full Text] [Related]
7. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
[TBL] [Abstract][Full Text] [Related]
8. Selective JAK1 inhibitors for the treatment of inflammatory bowel disease.
Nielsen OH; Boye TL; Gubatan J; Chakravarti D; Jaquith JB; LaCasse EC
Pharmacol Ther; 2023 May; 245():108402. PubMed ID: 37004800
[TBL] [Abstract][Full Text] [Related]
9. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
10. Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.
Sedano R; Ma C; Jairath V; Feagan BG
Gastroenterol Hepatol (N Y); 2022 Jan; 18(1):14-27. PubMed ID: 35505771
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease.
Gupta N; Papasotiriou S; Hanauer S
Expert Rev Clin Immunol; 2023; 19(9):1075-1089. PubMed ID: 37226522
[TBL] [Abstract][Full Text] [Related]
12. JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease.
Macaluso FS; Rodríguez-Lago I
Curr Drug Metab; 2020; 21(4):247-255. PubMed ID: 32156234
[TBL] [Abstract][Full Text] [Related]
13. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Kim JW; Kim SY
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768752
[TBL] [Abstract][Full Text] [Related]
14. JAK Inhibition: The Most Promising Agents in the IBD Pipeline?
Fernández-Clotet A; Castro-Poceiro J; Panés J
Curr Pharm Des; 2019; 25(1):32-40. PubMed ID: 30950344
[TBL] [Abstract][Full Text] [Related]
15. JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications.
Agrawal M; Kim ES; Colombel JF
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S755-S760. PubMed ID: 32006031
[TBL] [Abstract][Full Text] [Related]
16. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Salas A; Hernandez-Rocha C; Duijvestein M; Faubion W; McGovern D; Vermeire S; Vetrano S; Vande Casteele N
Nat Rev Gastroenterol Hepatol; 2020 Jun; 17(6):323-337. PubMed ID: 32203403
[TBL] [Abstract][Full Text] [Related]
17. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease.
Garrido I; Lopes S; Macedo G
Inflamm Bowel Dis; 2021 Nov; 27(12):2010-2022. PubMed ID: 33742651
[TBL] [Abstract][Full Text] [Related]
18. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease.
Ma C; Jairath V; Vande Casteele N
Best Pract Res Clin Gastroenterol; 2019; 38-39():101606. PubMed ID: 31327403
[TBL] [Abstract][Full Text] [Related]
20. Filgotinib for moderately to severely active ulcerative colitis.
Mannucci A; D'Amico F; El Saadi A; Peyrin-Biroulet L; Danese S
Expert Rev Gastroenterol Hepatol; 2022 Oct; 16(10):927-940. PubMed ID: 36278878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
